I lost an inspiration—my relative (Dr. PBA), a dedicated and talented doctor, who succumbed after a long and courageous battle with metastatic breast cancer and brain metastasis. She was the driving force behind my passion for oncology research, especially in breast cancer. Her journey began with a late and missed diagnosis, leading her across borders in search of evidence-based care, from one health care provider to another, and through relentless metastasis that even the most advanced and costly treatments could not halt.
She and her family sold everything to bear the crushing financial burden of her treatments. The emotional and physical toll on them—especially on her tireless husband, who sacrificed every penny of savings and property to give her a fighting chance at a longer, more comfortable life—was overwhelming. COVID-19 added another layer of complexity, complicating her care, disrupting her daughters’ medical and engineering education, and cutting off vital communication with her providers—all these unleashed multifaceted public health challenges.
Her treatment encompassed the full spectrum: chemotherapy, hormone therapy, surgery, radiation, and targeted therapies, including the latest advancements in antibody-drug conjugates like T-DXd. Through her, I witnessed both the evolution of cancer treatments and the promise of future breakthroughs. Her T-DXd therapy inspired me to generate real-world data, which I had the privilege of presenting at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. T-DXd showed significantly longer survival for HER2-low patients, with a median overall survival (mOS) of 9.3 months versus 4.3 months for those with brain metastasis, and 10.7 months versus 6 months for those without.
However, her case is a stark reminder that early intervention can offer better outcomes than treatment after heavy pretreatment, as in her case. As we mark Pink October, Breast Cancer Awareness Month, her story reminds us that the fight is far from over. We still have a long road ahead, and we must begin now.
Looking forward
Her journey is a poignant reflection of both the progress and the gaps in cancer care. Despite breakthroughs like T-DXd, which can offer hope to many, her story underscores the critical need for early detection, equitable access to treatment, and continued research into therapies that can address metastatic disease. It is stories like hers that remind us to keep pushing boundaries in science, medicine, and public health policy to ensure no one fights alone or without the tools they need.
For every success story, there are countless others still struggling, facing immense emotional, financial, and physical burdens. Her legacy, for me, is a constant call to action—a reminder that the progress we make in research and treatment must reach every corner of the world, and that survival statistics are not just numbers, but lives impacted, extended, and hopefully saved.
As we move forward in the fight against breast cancer, let her story inspire us to not just celebrate medical milestones, but to work toward a future where these devastating late-stage battles become far less common. Let’s channel her strength into meaningful action, transforming awareness into tangible support, research, and innovation that will bring us closer to ending this disease for all.
Vivek Podder is a physician in Bangladesh.
